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Abstract Effective antiretroviral therapy (ART) requires
excellent adherence. Little is known about how to improve
ART adherence in many HIV/AIDS-affected countries,
including China. We therefore assessed an adherence
intervention among HIV-positive patients in southwestern
China. Eighty subjects were enrolled and monitored for
6 months. Sixty-eight remaining subjects were randomized
to intervention/control arms. In months 7–12, intervention
subjects were counseled using EDM feedback; controls
continued with standard of care. Among randomized sub-
jects, mean adherence and CD4 count were 86.8 vs. 83.8%
and 297 vs. 357 cells/ll in intervention vs. control subjects,
respectively. At month 12, among 64 subjects who com-
pleted the trial, mean adherence had risen signiﬁcantly
among intervention subjects to 96.5% but remained
unchanged in controls. Mean CD4 count rose by 90 cells/ll
and declined by 9 cells/ll among intervention and control
subjects, respectively. EDM feedback as a counseling tool
appears promising for management of HIV and other
chronic diseases.
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Introduction
Successful antiretroviral therapy (ART) requires HIV-
positive patients to maintain high adherence to medication
regimes [1–4]. Although recent research suggests that non-
nucleoside reverse transcriptase inhibitor (NNRTI) based
regimens are more forgiving of imperfect adherence [5],
near perfect adherence that maximizes achievement of
sustained viral suppression remains a central goal of ther-
apy [6, 7]. Poor adherence also has important societal
consequences that extend beyond the individual. ART is
cost effective [8–11] but not free, and its cost-effectiveness
declines with reduced adherence, since the same expendi-
ture yields declining beneﬁts. Poor adherence also con-
tributes to drug-resistant strains of HIV, which are not only
associated with increased mortality in patients [12, 13] but
also can be transmitted to others [14, 15].
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DOI 10.1007/s10461-009-9615-1A number of interventions designed to improve ART
adherence have been assessed in recent years. Two rigor-
ous analyses of the efﬁcacy of intervention trials conducted
between 1996 and 2005 in high income countries [7, 16]
both found a modest, but statistically signiﬁcant, positive
effect on adherence in intervention vs. control subjects
when data from all the studies were pooled. This is
encouraging because it suggests that interventions can
beneﬁcially affect adherence behaviors. However, adher-
ence success varied substantially across the studies, with
only about 25% of interventions efﬁcacious. These and
more recent studies indicate that many of the most suc-
cessful interventions to date have involved providing
adherence- and treatment-related information to patients
and/or engaging them in interactive discussions of cogni-
tion, motivation, and expectations regarding adherence
[17–20].
Electronic drug monitors (EDM) have been instrumental
in monitoring ART adherence and in deﬁning the rela-
tionship between adherence and HIV-related clinical out-
comes [4, 21–23]. Two recent US-based studies also found
a positive effect on ART adherence of multi-faceted
interventions that included providing patients with their
EDM data. One found that a self-management intervention
implemented over 12 weeks increased the likelihood that
patients would take C80% of their pills [24]. While this
outcome is positive, 80% adherence is below the optimal
level for long-term viral suppression. Rosen et al. similarly
found that providing a contingency management interven-
tion to HIV-positive patients with a history of substance
abuse led to a signiﬁcant increase in adherence, from 61%
at baseline to 76% during the 16-week intervention phase,
and a decline in HIV viral loads, though the differences in
these outcomes were not statistically signiﬁcant after
16 weeks of follow-up [25].
China is experiencing one of Asia’s most serious HIV/
AIDS epidemics [26]. The most recent global and national
reports indicate that approximately 700,000 Chinese were
living with HIV/AIDS at the end of 2007 [27] and that new
infections in China continue to increase steadily [28]. The
majority of HIV-infected Chinese live in border provinces
such as Yunnan, Guangxi, and Sichuan, where the virus has
spread quickly due to a concurrent rise in injection drug use
(IDU), and in central provinces including Henan and
Anhui, where villagers were infected in the early-mid
1990s from contaminated blood collection practices [29–
31]. China has responded to its growing HIV/AIDS epi-
demic by rapidly expanding provision of free ART [32–
34]. By October 2007, approximately 32,000 individuals in
31 provinces across China were receiving ART [27]. A
2005 progress report on the ART scale-up noted poor
adherence among farmers in the central provinces, blaming
it for rising drug resistance in that region [35]. Yet, despite
awareness of the importance of ART adherence, little is
known about factors that inﬂuence adherence among
Chinese patients or about potentially effective adherence
interventions. As in most developing countries, the pub-
lished literature is limited to descriptive and qualitative
studies regarding barriers to adherence [36–38].
In the China Adherence for Life (AFL) study, we
assessed the impact of systematically integrating EDM data
into HIV clinical care—a process we term ‘EDM feed-
back’—on ART adherence among HIV-positive individu-
als in southwestern China. Our hypothesis was that
providing patients with counseling informed by objective
data on their recent adherence behavior would enhance the
effectiveness of adherence counseling, motivate patients to
improve their medication-taking, and thereby improve
ART adherence. We were implicitly testing the validity of
an information-motivation-behavior skills model that has
been used to describe the factors affecting adherence to
ART [39]. This intervention was the ﬁnal component of a
three-part project that also described barriers to adherence
[37] and, after measuring adherence using multiple meth-
ods over a 6-month period, identiﬁed the most accurate
measure of adherence in this Chinese population [40]. The
present paper presents the results of the intervention phase
of the study. Our primary aim was to determine whether
EDM feedback improved adherence 6 months after initia-
tion of the intervention. A secondary aim was to assess
whether EDM feedback improved HIV disease markers
(CD4 count and viral suppression).
Methods
Study Site and Subjects
Adherence for Life was a non-blinded randomized con-
trolled intervention trial conducted at the Dali Second
People’s Hospital (DSPH) in Dali, Yunnan province. Dali
is home to approximately 40,000 residents, primarily of
ethnic minority background. Over 80% of HIV-positive
individuals in Yunnan are estimated to have been infected
through IDU [41]. HIV-positive patients attending the
DSPH Dermatology and Sexually Transmitted Diseases
Clinic, where free ART has been provided since mid-2005,
were enrolled. When enrollment began in June 2006, a total
of 3 clinicians and 6 nurses were providing care and ART
to approximately 70 patients. They all received twice-daily
NNRTI regimens consisting of nevirapine or efavirenz plus
lamivudine with stavudine or zidovudine, which were
collected monthly at the DSPH.
Patients were eligible for participation if they were on
ART and aged 18 years or above; there were no exclusion
criteria. All eligible patients were approached by a
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123clinician, who described the study and referred interested
patients to a local study team member. The latter provided
a detailed explanation of the study’s purpose and require-
ments and obtained written informed consent prior to
enrolling each patient. All subjects received a monthly
stipend of 150 yuan (approximately US$19) as compen-
sation for lost work time and travel costs associated with
study participation. The study was approved by the insti-
tutional review boards of Boston University and Ditan
Hospital, Beijing.
Sample Size
Our target sample size of 80 was based on the number
needed to detect a 15% improvement in mean adherence in
the intervention arm, assuming a baseline adherence of
70%, with 90% power and alpha 0.05, and allowing for
10% attrition.
Pre-Intervention Procedures
In the pre-intervention period (months 1–6), we monitored
subjects’ adherence without providing the EDM data to
them or their clinicians (Fig. 1). To do so, at enrollment
each subject was given an EDM pill bottle (Med-ic
TM,
Ottawa, Canada) for one of his/her ART medications. In
most cases (64%) this was nevirapine, because it ﬁt most
easily into the EDM bottle, although a minority of subjects’
EDM bottles contained zidovudine or lamivudine. Subjects
were informed about the monitoring aspect of the EDM
bottles and, to ensure the collection of accurate data, were
instructed to keep the medication (but only this one med-
ication) in the bottle, not to play with it (opening/closing)
or to take out more than one dose at a time, and to recap the
bottle tightly after each use. Throughout the subsequent
12 months of data collection, when subjects made monthly
clinic visits to reﬁll their medications, a study team
member downloaded their EDM data. Each subject also
completed an adherence self-report that referred to medi-
cation-taking behavior during the previous week and
month.
Randomization
In month 6, subjects were stratiﬁed into high or low
adherence groups based on whether they had optimal
adherence during the pre-intervention period (deﬁned as
maintaining a mean of C95%, as measured by EDM,
throughout months 1–5). Subjects within each adherence
group were then randomized to the intervention or control
arm, ensuring that equal numbers of high and low adherers
were allocated to each arm. This was performed on site,
through a block randomization process as follows: at each
subject’s month 6 visit, the subject pulled an unmarked
allocation envelope, the inside of which had a single paper
stamped with either ‘‘intervention’’ or ‘‘control’’, from a
larger envelope that had originally held ten such allocation
envelopes, ﬁve for each arm. When each large envelope
was empty, it was replaced with another large envelope,
similarly containing ten allocation envelopes.
Enrollment: 
June-November 2006  
Pre- 
intervention  
period: 
Months 1-6 
June 2006- 
May 2007  
Intervention  
period: 
Months 7-12 
January- 
November 2007  
Baseline:  
80 patients on ART enrolled  
5 deaths; 3 from heroin overdose 
7 dropouts; 3 patients placed in 
detox centers, 4 patients moved, 
stopped ART, or left study  
At 6 months:  
68 patients  
Months 1-5 adherence assessed 
35 patients=“low” adherers  
(<95% in Months 1-5) 
33 patients=“high” adherers  
(  ≥95% in Months 1-5) 
18 randomized to  
Intervention Arm  
17 randomized to  
Control Arm  
17 randomized to  
Control Arm  
16 randomized to  
Intervention Arm  
1 dropout; patient 
in detox center 
17 completed   
study 
17 completed  
study 
14 completed  
study 
1 death;   
1 dropout; patient 
in detox center 
16 completed  
study 
1 dropout; patient 
in detox center 
Fig. 1 Study proﬁle. The study
involved 12 months of data
collection for each subject; with
rolling admission from June to
November 2006, Months 1–6 of
data collection took place from
June 2006 to May 2007 and
Months 7–12 of data collection
took place from January to
November 2007
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In the intervention period (months 7–12), when interven-
tion subjects came to the clinic for a monthly visit, a study
team member downloaded and reviewed the subject’s
previous month’s EDM data. Each subject found to be less
than 95% adherent according to the EDM data was ‘ﬂag-
ged’ for counseling with a clinic physician or nurse uti-
lizing the EDM information immediately following regular
clinic visit activities. The data were provided to both the
subject and his/her clinician as a printout summarizing the
percent of doses taken, the percent of doses taken on time,
and a visual display of doses taken by time. This process of
ﬂagging and counseling was speciﬁc to each clinic visit,
such that if a subject was counseled in Month 8 but had
EDM-measured adherence C95% at the Month 9 visit, no
ﬂagging for counseling occurred.
In each counseling session, the clinician reviewed the
EDM printout with the subject, explored reasons for missed
or off-time doses, and inquired about problems or chal-
lenges the subject might be having. Beyond this, counsel-
ing sessions did not follow a script. This was designed to
accommodate each clinician’s counseling style, allow for
an individually-focused discussion of adherence behavior,
and encourage each subject-clinician pair to devise per-
sonalized strategies to improving adherence. In this regard,
the EDM feedback provided data to inform and thereby
enhance the counseling, but did not dictate precisely how
the counseling should be performed. In the event that
subjects did not immediately offer reasons for missed or
off-time doses, clinicians were advised to say: ‘‘Let’s talk
more about any problems that you had last month.’’ Most
counseling sessions were completed within 10–15 min.
In the control arm, subjects continued to provide their
EDM data to a study team member at their monthly visits,
but these data remained blinded to both subjects and cli-
nicians. However, control subjects whose monthly written
self-reports indicated \95% adherence were also ﬂagged
by a study team member for further counseling with a
clinician. Thus, subjects in both groups whose adherence in
the previous month appeared to be below 95% were
identiﬁed for counseling, with the difference being the
ﬂagging mechanism—EDM for intervention subjects and
self-reported adherence for controls. In the counseling
sessions with control subjects, which were guided by self-
reported adherence, the standard of care in China, clini-
cians were similarly advised to inquire about recent prob-
lems that might have affected dose-taking.
To ensure that intervention procedures would be fol-
lowed, members of the Boston-based team reviewed pro-
cedures on-site and conducted training with the local study
team and clinicians prior to implementation of the inter-
vention. The training focused on the set-up and provision
of the EDM print-out to subjects and clinicians, which
involved a 1/2-day period of overview and practice with
the nurses and local study team, and the adherence coun-
seling sessions. The latter included a 3-h group training
with all the clinicians at the DSPH clinic counseling that
emphasized: (1) the goal of counseling was to help subjects
to improve their medication-taking behavior, not to scold
them about poor adherence; (2) the importance of dis-
cussing the EDM print-out with subjects; (3) posing prac-
tical questions to subjects on ways to improve adherence in
the next month. Subsequent practice and role-playing were
then conducted in two 3-h sessions.
Measures
Our primary outcome variable was adherence as measured
by EDM. Speciﬁcally, we used the EDM adherence metric
that was found to be most strongly associated with viral
suppression (HIV RNA\400 copies/ml) in analysis of the
pre-intervention data, EDM ‘proportion taken within dose
time’ [40]. This measure estimated monthly adherence as
the proportion of prescribed doses taken on time, e.g.,
within 1 h of scheduled dose time ([number of doses taken
±1 h of dose time]/[total number of prescribed doses]).
Dose times were selected by patients in consultation with
their clinician, and could be changed if necessary. How-
ever, the two daily doses had to be spaced 12 h apart to
optimize the pharmacokinetics of the drugs. Thus a patient
was free to choose 9 am/9 pm as his/her dose times, but
could not choose 9 am/8:30 pm Any dose taken outside of
this ±1 h window was considered non-adherent for that
dose. For more details, see Gill et al. 2009 [40].
Self-reported adherence, used to identify low adherers in
the control group during the intervention period, was
assessed from subjects’ written responses to questions on
the monthly form. These included: (1) a visual analog scale
(VAS) of proportion of ART medications taken in the
previous month; (2) a series of 6 yes/no questions about
medication-taking behavior in the previous month (being
careless, forgetting, stopping treatment due to feeling bet-
ter, not taking medications while at work, taking pills early
or late, sharing medications); and (3) two quantitative
questions on the number of days medications were not
taken and number of days medications were taken early or
late. A subject in the control arm was ﬂagged as a ‘low
adherer’ if he/she reported \95% on the VAS, answered
‘yes’ to any one of the six behavioral questions, or reported
more than 0 days for either of the quantitative questions.
CD4 count and HIV viral load were tested at baseline,
randomization (month 6), and post-intervention (month
12). CD4 counts were measured at a local laboratory
by ﬂow cytometry (FACSCalibur, Becton–Dickinson,
San Carlos, CA, USA). We calculated change in CD4
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month 12 CD4 count. HIV viral loads were measured with
an Organon Teknica NucliSens analyzer (BioMerieux,
Boxtel, Netherlands), at the Center for Disease Control
laboratory in Kunming, the provincial capital. The lower
limit of the viral load assay was 400 copies per ml.
Statistical Analysis
In the assessment of the intervention, we included data for
the 64 subjects who completed the study. Data were ana-
lyzed using SAS version 9.1 (SAS Institute, Cary, NC,
USA). We compared mean adherence between the inter-
vention and control groups at months 6 and 12, mean
within-group adherence between the pre-intervention per-
iod and intervention period, CD4 count at months 6 and 12,
and change in CD4 count from months 6 to 12 between
groups using Student’s t-tests. Cochran Mantel–Haenszel
(CMH) v
2 tests were used to compare proportions achiev-
ing 95% adherence and proportions with HIV RNA\400
copies/ml at month 12. Demographic and socioeconomic
characteristics of intervention and control subjects were
compared using t-tests for continuous variables and CMH
tests for categorical variables. Findings are presented as
means with standard deviations (SD) or risk ratios (RR)
and 95% conﬁdence intervals (CI), with corresponding test
statistics. All inferences were made based on a type I error
rate equal to 0.05. Each analysis was also adjusted for
education, the only variable for which there was a signif-
icant difference between intervention and control subjects
at randomization. Because effect size estimates did not
change signiﬁcantly, and due to our small sample size, we
present only the unadjusted results.
Five subjects had months where data were missing due
to EDM pill bottle malfunctions. In these cases, the pre-
vious month’s adherence was used in calculations of sin-
gle-month adherence (e.g., month 11 was used for month
12 adherence). For cumulative calculations (e.g., adherence
during the pre-intervention or intervention period), the
missing month’s data were excluded and the cumulative
indicator was calculated using 5 months of EDM data.
Repeated openings within the same scheduled dose time
were excluded.
Results
Subject Flow
Subject enrollment took place between June and November
2006. During this period, a total of 97 eligible patients
attended the DSPH, all of whom were offered participation
in the study. Of these, 80 were enrolled. The main reasons
for non-participation were: (1) difﬁculty completing inter-
views due to language barriers (some clinic patients spoke
a very heavy local dialect); (2) lack of availability to
complete interviews; and (3) unwillingness to use the EDM
pill bottle. Following 12 months of participation by each
subject, data collection was completed by the end of
November 2007. Of enrolled subjects, ﬁve died, and seven
dropped out during the 6-month pre-intervention period
(Fig. 1). The remaining 68 subjects were randomized into
intervention and control arms, of which 64 completed the
intervention period: 31 intervention subjects and 33
controls.
Characteristics of Subjects
Randomized subjects only differed in education back-
ground, with a higher proportion of intervention subjects
having completed senior high or technical school (29 vs.
3%; CMH test statistic = 9.27; P-value = 0.01) (Table 1).
Fifty-one percent had been infected through IDU, although
only 13% reported heroin use in the 3 months prior to
randomization. Twenty-nine percent were treatment-naı ¨ve
at baseline; mean duration on ART at month 6 was
10.9 months. Mean CD4 count was slightly higher among
controls (357 vs. 297 cells/ll; t-test statistic = 1.42; P-
value = 0.16). The proportion of subjects with HIV RNA
\400 copies/ml was 88% in each arm (CMH test statis-
tic = 0.0082; P-value = 0.93). The mean adherence of all
randomized subjects was 85.7% during the pre-intervention
period.
Effect of EDM Feedback on Adherence
We ﬁrst compared adherence data at randomization (month
6) and month 12 (Table 2). At randomization, mean
adherence among intervention and control subjects was
comparable at 86.8 and 83.8%, respectively (t-test statis-
tic =- 0.59; P-value = 0.56). However, at month 12,
mean adherence among intervention subjects was much
higher than among controls: 96.5 vs. 84.5% (t-test statis-
tic =- 3.20; P-value = 0.003). Comparing within-arm
changes between randomization and month 12, mean
adherence of intervention subjects increased (86.8–96.5%,
t-test statistic =- 2.84; P-value = 0.008), with no signif-
icant change among controls (83.8 vs. 84.5%, t-test sta-
tistic =- 0.14; P-value = 0.89). Similarly, contrasting
mean adherence throughout the pre-intervention and
intervention periods revealed a signiﬁcant improvement in
the intervention arm (89.5 vs. 96.4%; t-test statistic =
-2.71; P-value = 0.01), but no change in the control arm
(87.3 vs. 84.1%, t-test statistic = 0.68; P-value = 0.50).
Point estimates for mean monthly adherence revealed
signiﬁcantly higher monthly adherence rates among the
584 AIDS Behav (2010) 14:580–589
123intervention arm than controls (P-value \0.001–.017 for
months 7, 8, 10–12; P-value = 0.06 for month 9), largely
duetothesharpincreaseinadherenceamongpreviouslylow
adherers (those with \95% adherence before randomiza-
tion). As shown in Fig. 2, mean monthly adherence in this
intervention arm subgroup rose dramatically between
months 6 and 8 and remained close to 95% throughout the
intervention period, whereas adherence among control arm
low adherers did not change signiﬁcantly.
In addition, EDM feedback improved the likelihood of
achieving 95% adherence by month 12 and throughout the
intervention period (see Table 2). Among intervention
subjects, 26/31 (83.9%) had C95% adherence in month 12,
compared to 13/33 (39.4%) among controls (RR = 2.1; CI:
1.4–3.3, CMH test statistic = 13.08; P-value = 0.0003).
The effect of the intervention was more pronounced among
low adherers, among whom 12/16 (75.0%) intervention
subjects, but only 2/17 (11.8%) controls achieved C95%
adherence in month 12 (RR = 6.4; CI: 1.7–24.2, CMH test
statistic = 13.08; P-value = 0.0003). Even those with high
adherence prior to randomization appeared to beneﬁt
from EDM feedback, with 14/16 intervention (93.3%) vs.
11/16 control subjects (68.8%) achieving C95% in month
12 (RR = 1.4; CI: 1.0–1.9, CMH test statistic = 2.90;
P-value = 0.09).
Effect of EDM Feedback on Markers
of HIV Progression
EDM feedback was not signiﬁcantly associated with mean
CD4 count at Month 12 (see Table 2). However, the pro-
portion of subjects that experienced an increase in
CD4 count was higher in the intervention arm (22/31
(71.0%) vs. 15/31 (48.4%) (CMH test statistic = 3.23;
P-value = 0.07). More strikingly, the mean CD4 count
rose by 90 cells/ll (SD 171.6) in intervention subjects
during the intervention period, compared to a mean
decline of 9 cells/ll (SD 152.6) (t-test statistic =- 2.4;
P-value = 0.02) among controls. The proportion of sub-
jects with HIV RNA\400 copies/ml at month 12 was high
in both arms, and did not differ signiﬁcantly.
Discussion
This study has demonstrated that a simple intervention
involving monthly adherence counseling based on EDM
feedback signiﬁcantly improved mean adherence among
Chinese ART patients. CD4 counts were also signiﬁcantly
increased, though there was no effect on the degree of viral
suppression at HIV RNA \400 copies/ml. In contrast to
Table 1 Characteristics of subjects at randomization (6 months)
Characteristic Intervention (n = 34) Control (n = 34) Test statistic
a P-value
Age (years) 36.1 (8.3) 35.1 (8.0) -0.46 0.65
Male, n (%) 25 (74) 25 (74) 0.00 1.000
Highest education level achieved, n (%) 9.27 0.01
Primary school 7 (21) 13 (38)
Middle school 17 (50) 20 (59)
Secondary school 10 (29) 1 (3)
Married, n (%) 19 (56) 18 (53) 0.06 0.80
Han Ethnic background, n (%) 14 (41) 17 (50) 0.53 0.47
Household size, persons (SD) 4.2 (1.5) 4.5 (1.4) 1.13 0.26
Employed, n (%) 10 (31) 12 (38) 0.27 0.60
Infected through injection drug use, n (%) 18 (53%) 17 (50) 0.06 0.81
Used heroin in previous 3 months, n (%) 4 (12) 5 (15) 0.13 0.72
Treatment-naı ¨ve at baseline (month 0), n (%)
b 9 (26.5) 10 (29.4) 0.07 0.79
Time on antiretroviral therapy, months (SD) 10.5 (4.3) 11.3 (6.6) 0.59 0.56
CD4 count, mean cells/ll (SD) 297 (145) 357 (196) 1.42 0.16
HIV RNA\400 copies/ml (%) 30 (88) 28 (88) 0.008 0.93
Proportion with optimal adherence, n (%)
c 0.06 0.81
High (C95%) 16 (47) 17 (50)
Low (\95%) 18 (53) 17 (50)
a Test statistics are from Cochran Mantel–Haenszel v
2 tests for categorical variables and Student’s t tests for continuous variables
b Treatment-naive was deﬁned as B2 weeks duration on antiretroviral therapy
c Optimal adherence was deﬁned as maintaining mean adherence C95% during months 1–5 according to EDM and calculated as: # prescribed
doses taken ±1 h prescribed dose time/prescribed doses
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123previous studies that utilized EDM feedback, we found an
impact on adherence that was both very high—above the
95% threshold—and sustained, with mean adherence above
95% throughout the 6-month intervention period.
These ﬁndings add to our understanding of the potential
effect of EDM feedback as an adherence intervention tool
in several important ways. First, the effect on adherence
was immediate—in the ﬁrst 2 months—and occurred
Table 2 Adherence and markers of HIV progression: intervention and control subjects
Outcomes Intervention
(N = 31)
Control
(N = 33)
Test statistic
a P-value Risk ratio
(95% CI)
Adherence
Mean adherence, % (SD)
b
Month 6 86.8 (18.5) 83.8 (21.8) -0.59 0.5581 –
Month 12 96.5 (4.8) 84.5 (21.0) -3.20 0.0029 –
In pre-intervention period
c 89.5 (13.8) 87.3 (16.7) -0.55 0.5837 –
In intervention period
c 96.4 (3.4) 84.1 (21.4) -3.24 0.0027 –
Proportion achieving C95% adherence, n/N (%)
Month 12 26/31 (83.9) 13/33 (39.4) 13.08 0.0003 2.1 (1.4–3.3)
High (C95%) 14/15 (93.3) 11/16 (68.8) 2.90 0.0885 1.4 (1.0–1.9)
Low (\95%) 12/16 (75.0) 2/17 (11.8) 13.08 0.0003 6.4 (1.7–24.2)
In intervention period (mean) 23/31 (74.2) 11/33 (33.3) 10.55 0.0012 2.2 (1.3–3.8)
Markers of HIV progression
CD4 count
Month 12, mean cells per ll (SD) 401 (256) 357 (157) -0.83 0.4100
Change in CD4 count, month 6 to month 12
Mean change in cells/ll (SD) 90.0 (171.6) -8.8 (152.6) -2.4 0.0197
Proportion whose CD4 count rose, n (%) 22 (71.0) 15 (48.4) -3.23 0.0722 1.5 (1.0–2.2)
HIV RNA\400 copies/ml, month 12, n (%) 27 (87.1) 31 (93.9) 0.87 0.3518 0.92 (0.79–1.1)
a Test statistics are from Cochran Mantel–Haenszel v
2 tests for categorical variables and Student’s t-tests for continuous variables. Student’s
t tests for continuous variables except as noted
b Adherence measured via electronic drug monitor, calculated as: # prescribed doses taken ±1 h prescribed dose time/prescribed doses
c Pre-intervention period: months 1–6; Intervention period: months 7–12
50% 
55% 
60% 
65% 
70% 
75% 
80% 
85% 
90% 
95% 
100% 
1 2 3 4 5 6 7 8 9  10  11  12 
Low adherers, intervention group 
Low adherers, control group 
High adherers, intervention group 
High adherers, control group 
Adherence
Study Month 
Fig. 2 Monthly mean
adherence among intervention
and control subjects, stratiﬁed
by mean adherence in pre-
intervention period: high
(C95%) vs. low (\95%)
adherers. Adherence measured
via electronic drug monitor,
calculated as: # prescribed doses
taken ±1 h prescribed dose
time/prescribed doses
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123mainly among poorly adherent patients. This suggests that
ART patients in China are capable of dramatic improve-
ments in adherence, though the question of sustainability of
effect remains unanswered. It is also consistent with a
recent analysis which found that ART intervention studies
that only enrolled participants with known or anticipated
adherence issues were more likely to show a beneﬁt [16].
In China, as in most developing countries, the enormous
ﬁnancial and public health ramiﬁcations of drug resistance
and expensive second line regimens, in addition to
increased mortality associated with poor ART adherence,
argue strongly for focusing efforts to improve adherence
among low adherers. That said, our ﬁndings suggest ben-
eﬁts to EDM feedback even among patients whose adher-
ence is excellent; in our high adherence group, intervention
subjects were less likely than controls to experience a
decline in adherence to below 95% over time.
Relative to other ART adherence intervention studies
that have utilized EDM feedback, AFL was simpler,
involving provision of EDM-enhanced counseling only,
without accompanying additional information, speciﬁc
skills development, or ﬁnancial incentives [24, 25]. This
indicates that a focus on discussion of recent adherence
behavior that relies on accurate information may be a
particularly strong motivator for some patients, and is
sufﬁcient to produce meaningful behavior change. Inter-
vention patients also maintained a signiﬁcantly higher
adherence level over a longer period (6 months) compared
to other studies (3–4 months) [24, 25], suggesting the
potential for sustained impact.
This study was not powered to detect a change in viral
suppression and thus we were not surprised at the lack of
such an effect. A number of other adherence intervention
studies similarly successfully improved patients’ adherence
but did not observe signiﬁcant changes in viral load mea-
sures [42, 43], while a recent meta-analysis of 18 ART
adherence interventions also found an overall small but
signiﬁcant adherence effect but no improvement in viral
suppression. In our study, high rates of pre-randomization
viral suppression (88%) made it unlikely that we could
show signiﬁcant changes in viral load parameters. This
high rate of viral suppression in the context of mean
adherence in the 85% range was probably the result of
several factors, including the fact that all patients were on a
NNRTI-based regimen that is more forgiving than protease
inhibitor-based regimens when patients are less-than-opti-
mally adherent [5].
An obvious question arises: why was EDM feedback so
effective? Unfortunately, without detailed process data, we
can only speculate about this, but several factors are likely
salient, varying in importance for different patients. Some
patients may be motivated by the ability to follow their
progress, with no chance for self-delusion, much like
individuals trying to lose weight may be encouraged by
having to step on a scale periodically. Others may strongly
desire to avoid enhanced counseling with a clinician,
especially because EDM information precludes pretending
that everything is okay, unlike self reports. This tendency
may be reinforced by a particularly Chinese cultural ten-
dency to highly respect clinicians. For those who struggle,
the EDM feedback-based counseling provides an oppor-
tunity for meaningful discussion about medication-taking
issues speciﬁc to the individual and points in time, which
may provide certain patients just the focused discussion of
behavior changes that they need. Its ultimate success
depends on the counselor’s approach, as well as on the
patient’s attitude and other variables that affect medication-
taking.
It is also important to recognize that the intervention
included not just the counseling sessions, but a relatively
reliable ﬂagging system for the counseling (EDM data).
Low adherers inclined to hide their poor adherence could
do so if they were in the control group by self-reporting
adherence above 95%, unlike those in the intervention
group. Our data on the number of intervention vs. control
group subjects who were ﬂagged for counseling sessions—
consistently higher in the former—support this hypothesis.
We also note a number of study limitations. First, the
lack of a script for the EDM feedback counseling, while
allowing clinicians ﬂexibility, precluded collection and
analysis of counseling process data. Further research is
needed to understand better how EDM feedback alters the
style and content of counseling sessions. Second, while the
duration of the intervention (6 months) is one of the lon-
gest in the adherence literature, it is unclear how long EDM
feedback must be continued to sustain the effect on
adherence. Third, this study included no period of post-
intervention follow-up, and thus the long-term impact
without the intervention is unknown and needs assessment.
Lastly, we conducted the study in a distinctive cultural
context—Chinese patients who were predominantly former
IDUs. Whether EDM feedback would be as effective in
other cultural contexts, or even in China in non-former IDU
populations, remains to be tested.
Our results also raise several operational questions.
First, does EDM feedback have a persistent effect after
discontinuation, or must it be continued indeﬁnitely? Sec-
ond, while we used clinicians (both physicians and nurses)
for the adherence counseling, it would be helpful to
determine whether EDM feedback is effective if counsel-
ing is done by peers or family members. Third, how easily
can the technical requirements of EDM feedback (com-
puters, pill bottles, staff training) be adapted to other set-
tings and at larger scales? We found that EDM feedback
required a moderate degree of training. The basics of EDM
use required a full day of training and practice with local
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123staff; the intervention-related ﬂagging of low adherers and
counseling required another 1–1.5 days. After the ﬁrst
month or so of actual implementation, both staff and
patients were comfortable with the technical details of
EDM use and sustaining the intervention, once begun, was
not burdensome. This is relevant since there is a prevailing
sentiment in the literature that EDM are too complex and
technically demanding to be of broad usefulness.
The results of this study show that adherence counseling
utilizing EDM feedback was effective at achieving sus-
tained rates of optimal adherence and that these behavioral
changes translated into improved CD4 counts, an important
marker of HIV progression. We conclude that this is a
promising approach to improving adherence, with potential
for wide applicability in other HIV populations and also
possibly in the management of other chronic diseases.
Given the distinctive context in which we conducted the
study, further evaluation in diverse populations and settings
is warranted.
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